Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical genetics

31 May 2024

Abstract excerpt

There are only five approved small molecule antiviral drugs for treating COVID-19. Among them, four are nucleotide analogues (remdesivir, JT001, molnupiravir, and azvudine), while the other four are protease inhibitors (nirmatrelvir, ensitrelvir, leritrelvir, and simnotrelvir-ritonavir). Antiviral resistance, unfavourable drug‒drug interaction, and toxicity have been reported in previous studies1-6. Thus there is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39309487
DOI: 10.1016/j.apsb.2024.05.026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of novel small-molecule inhibitors of SARS-CoV-2 by chemical geneticsPMID 39309487Read ↗

Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screeningSemantic proximity Read ↗

Potent antiviral activity of simnotrelvir against key epidemic SARS-CoV-2 variants with a high resistance barrierSemantic proximity Read ↗

SARS-CoV-2 3CLpro mutations T21I and E166A confer differential resistance to simnotrelvir, bofutrelvir, and ensitrelvir.Semantic proximity Read ↗

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsSemantic proximity Read ↗

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strainsSemantic proximity Read ↗

Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19Semantic proximity Read ↗

Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening.Semantic proximity Read ↗

SARS-CoV-2 Resistance to Small Molecule InhibitorsSemantic proximity Read ↗

Virtual screening FDA approved drugs against multiple targets of SARS‐CoV‐2Semantic proximity Read ↗

Novel Pan-Coronavirus 3CL Protease Inhibitor MK-7845: Bio-Logical and Pharmacological ProfilingSemantic proximity Read ↗

An Overview of SARS-CoV-2 Potential Targets, Inhibitors, and Computational Insights to Enrich the Promising Treatment StrategiesSemantic proximity Read ↗

Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.